source
- Novartis MS drug remibrutinib cuts relapse rates by about a third in Phase 3 trialsData presented at an MS conference in Toronto showed that Novartis' experimental therapy, remibrutinib, reduced the annualized relapse rate in relapsing‑remitting multiple sclerosis by roughly 35%…
- Roche signs up to $813M deal with Zymeworks for preclinical trispecific T cell engagerRoche announced a partnership with Zymeworks that includes an upfront payment of $55 million for worldwide rights to a trispecific T cell engager currently in preclinical development. The agreemen…